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original work is propObjective: Symptoms of acute retroviral syndrome (ARS) may be used to identify patients
with acuteHIV-1 infection who seekcare. ARS symptoms inAfricanadults differ by region.
We assessed whether reporting of ARS was associated with HIV-1 subtype in a multicentre
African cohort study representing countries with predominant HIV-1 subtypes A, C, and D.
Methods: ARS symptoms were assessed in adults enrolling at least 6 weeks after the
estimated date of infection in an acute and early HIV-1 infection cohort study. HIV-1
subtype was determined by POL genotyping. We used log-binomial regression to
compare ARS symptom prevalence among those with subtype A vs. C or D, adjusting
for sex, time since enrolment, and enrolment viral load.
Results: Among 183 volunteers ascertained within 6 weeks after estimated date of
infection, 77 (42.0%) had subtype A, 83 (45.4%) subtype C, and 23 (12.6%) subtype D
infection. Individuals with subtype A were 1.40 (95% confidence interval: 1.17, 1.68)
times as likely as individuals with subtypes C or D to report any ARS symptoms; each
individual symptom other than rash was also more prevalent in subtype A than in
subtype C or D, with prevalence ratios ranging from 1.94 (1.40, 2.70) for headache to
4.92 (2.24, 10.78) for lymphadenopathy.
Conclusion: Individuals with subtype A were significantly more likely than individuals
with subtypes C or D to report any ARS symptoms. HIV-1 subtypes may help explain
differences in ARS that have been observed across regions in Africa, and may impact the
yield of symptom-based screening strategies for acute HIV infection detection.
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2542 AIDS 2017, Vol 31 No 18IntroductionPrompt identification and treatment of adults newly
infected with HIV-1 can dramatically reduce onward
transmission and improve the health of the infected
individual [1]. Identifying adults with acute HIV-1
infection (AHI), a substantial portion of whom seek
urgent care even in resource-constrained settings [2],
therefore has tremendous public health importance [3].
Unfortunately, AHI detection has not been emphasized
in Sub-Saharan Africa (sSA), where the epidemic burden
is greatest [4,5].
Across sSA, AHI symptom prevalence has varied
considerably, with higher estimates reported in Kenya
[6] than in Uganda [7] and Zambia [8]. Symptoms
develop approximately 2 weeks after HIV-1 acquisition,
just before plasma viral load peaks [9,10], and the number
of symptoms correlates with higher plasma viral load
before seroconversion [11]. Thus, strategies aiming to
diagnose symptomatic AHI patients at care seeking may
identify those with more severe symptoms and higher
peak [11] and set point [9,12] viral load.
Although infection with HIV-1 subtypes C or D (vs.
subtype A) has predicted faster progression to AIDS and
death in several studies in Africa [12–15], little systematic
research has been conducted on the clinical manifesta-
tions of AHI in relation to subtype. As substantial
geographical differences in ARS have been documented
in sSA [2,6–8] and HIV-1 subtype varies geographically,
we hypothesized that the occurrence of symptoms
around the time of seroconversion could be correlated
with HIV-1 subtype. We sought to test this hypothesis in
the largest seroconverter cohort study from Africa, a
research collaboration of nine clinical research centres
(CRC), representing countries with predominant HIV-1
subtypes A, C, or D [16].Methods
Study design and procedures
Data derived from ‘protocol C’ of the International AIDS
Vaccine Initiative (IAVI), a multicentre early HIV infection
cohort study [15]. As described previously [16], adults at
risk of HIV-1 were enrolled into a prospective cohort study
across CRCs in Kenya, Uganda, Rwanda, Zambia, and
South Africa. These HIV incidence cohorts included
predominantly: cohabiting heterosexual partners of an
HIV infected, antiretroviral therapy-naı̈ve person (Zambia;
Rwanda; Uganda); sex workers and their clients, or clients
with a sexually transmitted infection (Kenya); MSM
(Kenya and Rustenburg, South Africa); or adolescents
(Cape Town). Incidence study volunteers were tested for
HIV-1 monthly or quarterly (depending on site) as
described previously [17,18].Volunteers with incident HIV infection were invited to
enrol into protocol C between February 2006 and
December 2011. At enrolment, all patients completed a
standardized questionnaire asking whether they had
experienced symptoms consistent with acute retroviral
syndrome (ARS) in the past 90 days: fever, headache,
myalgia/arthralgia, fatigue, anorexia, pharyngitis, diar-
rhoea, night sweats, skin rash, lymphadenopathy, oral
ulcers, or ‘other’. Enrolment viral load [16] was measured
and HIV-1 subtype was determined by sequencing the
POL (HIV-1 genome) region [19].
The ethical review boards of all participating CRCs
approved the study protocol and all study volunteers
provided written informed consent.
Estimated date of infection and timing of
symptom ascertainment
The estimated date of HIV-1 infection (EDI) was
determined as follows [20]: 10 days before the sample
collection date when the sample had a positive RNA viral
load, negative p24 antigen and negative HIV-1 serology;
14 days before a positive p24 antigen test (regardless of
RNA result) with negative HIV-1 serology; 19 days
before the date that rapid HIV-1 antibody tests were
discordant (regardless of p24 antigen or RNA result); or
the mid-term date between a previously negative and
subsequently fully positive HIV-1 serologic test (two
rapid tests conducted in parallel) [2].
To limit recall error and maximize questionnaire
sensitivity, we restricted the current analysis to patients
who enrolled in protocol C within 6 weeks of EDI [15],
based on our earlier finding that reported symptom
prevalence was considerably lower in patients evaluated
more than 6 weeks vs. within 6 weeks after EDI [21].
Data analysis
We first calculated descriptive statistics, including
prevalence of each ARS symptom and prevalence of
‘any’ symptom by HIV-1 subtype. We then used two sets
of multivariable log-binomial regression models to
estimate the association between HIV-1 subtype and
reporting any ARS symptom. In one set, we included
enrolment log10 viral load to estimate the direct effect (i.e.
not mediated through viral load) of subtype on ARS
symptoms; in the other, we excluded viral load to
estimate the total effect of subtype. In both sets, we started
with a full model containing two potential confounders –
sex and time between EDI and enrolment – that have
been reported as being associated with ARS symptoms
[21,22] and were associated with subtype in our study
(because of differences in population types and enrolment
timing across sites). To maximize precision, we dichoto-
mized the exposure in each set of models as subtype A vs.
subtype C or D (combined) after we observed that
symptom prevalence and other characteristics were
similar for subtypes C and D (Supplemental Figure S1,
HIV-1 subtype in a multicentre cohort study Sanders et al. 2543http://links.lww.com/QAD/B169, Supplemental Table
S1, http://links.lww.com/QAD/B169). We used back-
ward selection with a¼ 0.05 to sequentially remove
variables and arrive at a final model within each set.
To explore the possibility that differences in reported
symptoms across subtypes might be because of differential
symptom reporting/ascertainment and/or unmeasured
confounding across study centres, we conducted a
sensitivity analysis of ARS symptoms by subtype only
among volunteers at the two centres (Masaka and Kilifi),
where cases across the three subtypes were enrolled.
Multivariable analyses were not possible in this subset.
Additionally, we examined univariable associations
between 37 common human leucocyte antigen (HLA)
variants (see Supplemental List S1, http://links.lww.
com/QAD/B169) and ARS symptom reporting (any vs.
none) to determine (accounting for multiple compar-
isons) whether adjustment for any of these HLA types was
needed. We performed a similar analysis to assess whether
calendar year of enrolment was associated with ARS
symptom reporting.Results
A total of 183 volunteers were ascertained within 6 weeks
following EDI, 77 (42%) with subtype A and 106 (58%)
with subtype C or D infection (Table 1). Overall,
approximately one-third of participants were female, with
higher proportions of females among those with subtype
C or D. Participants with subtype A were on average 3
years younger than participants with subtype C or D.
Most volunteers with subtype A enrolled in Kigali orTable 1. Volunteer characteristics at enrolmenta.
Characteristic Overall
N (%) female 63 (3








Cape Town 3 (1
Copperbelt 17 (9
Rustenburg 6 (3
Number (%) in risk group:b
Serodiscordant couples 120 (6
MSM 45 (2
Other/don’t know 18 (9
Median (interquartile range) days since EDIb 25 (1
Median (range) enrolment log10 viral load 5.0 (1
Median (range) number of ARSc symptoms per participant b 3 (0
ARS, acute retroviral syndrome; EDI, estimated date of HIV-1 infection.
aAll within 42 days of estimated infection acquisition date.
bSubtype A vs. subtype C or D comparison statistically significant at a¼0
cAcute retroviral syndrome.Kilifi (Table 1), and most with subtype C enrolled in
Lusaka or Copperbelt Province (Supplemental Table S1,
http://links.lww.com/QAD/B169). Participants with
subtype D enrolled only in Masaka, Kilifi, and Entebbe
(Supplemental Table S1, http://links.lww.com/QAD/
B169). Of those with known risk group status, persons
with subtype A infections were evenly split between
MSM and serodiscordant heterosexual couples, whereas
most with subtype C or D infections were members of
serodiscordant couples. Persons with subtype A infection
were enrolled a few days earlier on average and had a
slightly higher viral load than did persons with subtypes
C or D.
Overall, 84.4% (95% confidence interval: 76.3–92.5%) of
subtype A volunteers reported any ARS symptoms,
compared with 60.4% (50.1–68.8%) of volunteers with
subtypes C or D (Fig. 1). The median (range) number of
symptoms per volunteer was 5 (0, 11) for subtype A, 2 (0,
8) for subtype C, and 1 (0, 8) for subtype D. In Kigali and
Kilifi, the median was 4 (0, 8) and 7 (0, 11) among their
29 and 37 subtype A volunteers, respectively. The
percentage of subtype A participants reporting each of the
individual symptoms ranged from 6.5% (1.0–12.0%) for
skin rash to 67.5% (57.1–78.0%) for fever, compared with
a range of 6.6% (1.9–11.3%) for skin rash to 32.1%
(23.2–41.0%) for headache among those with subtypes C
or D. Each of the specific symptoms other than rash
(unadjusted prevalence ratio¼ 0.98, 95% confidence
interval: 0.32–2.98) was more prevalent in subtype A
than in subtype C or D (combined), with the unadjusted
prevalence ratio ranging from 1.94 (1.40, 2.70) for
headache to 4.92 (2.24, 10.78) for lymphadenopathy. The
corresponding prevalence ratio for reporting any
symptoms was 1.40 (1.17, 1.68). Findings were similar(N¼183) Subtype A (N¼77) Subtype C or D (N¼106)
4.4) 21 (27.3) 42 (39.6)
6–58) 27 (19–52) 30 (16–58)
8.0) 29 (37.7) 4 (3.8)
2.0) 5 (6.5) 17 (16.0)
5.7) 37 (48.0) 10 (9.4)
.7) 4 (5.2) 1 (1.0)
5.1) 1 (1.3) 45 (42.5)
.2) 1 (1.3) 3 (2.8)
.7) 0 (0.0) 3 (2.8)
.3) 0 (0.0) 17 (16.0)
.3) 0 (0.0) 6 (5.7)
5.6) 36 (46.8) 84 (79.3)
4.6) 35 (45.4) 10 (9.4)
.8) 6 (7.8) 12 (11.3)
9–33) 21 (18–32) 26 (21–33)
.4–7.3) 5.2 (1.4–7.3) 4.9 (2.6–7.0)
, 11) 5 (0, 11) 2 (0,8)
.05.
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Fig. 1. Prevalence of acute retroviral syndrome symptoms by dichotomized HIV-1 subtype, all sites. Statistically significant at
a¼0.05. ySymptoms reported under ‘other’ were gastrointestinal symptoms, ophthalmic symptoms, cough, dizziness, malaise,
and rhinitis.but less precise in the sensitivity analysis restricted to Kilifi
and Masaka volunteers (Supplemental Figure S2, http://
links.lww.com/QAD/B169).
None of the 37 HLA types we examined was associated
with ARS symptoms (results available on request), nor
was calendar year of enrolment (P¼ 0.8), so we did not
include HLA type or calendar time in our models. In both
sets of multivariable models (with and without viral load),
neither of the potential confounders (sex, time since
enrolment) was selected for the final model. The total
effect estimated in the final model was thus identical to
the unadjusted prevalence ratio (1.40) above. The
prevalence ratio arising from the final model with viral
load included was 1.47 (1.20, 1.80). The similarity of this
result to the estimate from the model without viral load
suggests that the relationship between viral subtype and
ARS symptoms is not mediated through viral load.Discussion
ARS symptoms were more prevalent in patients infected
with HIV-1 subtype A vs. subtype C or D in our
multicentre cohort in Africa, a difference that was
independent of viral load [6], HLA type, sex, and time of
enrolment. These findings, from the largest study of ARS
symptoms by HIV-1 subtype to date, may help to explain
differences in ARS reporting across previous studies from
different regions of sSA. Indeed, the greater number of
symptoms per participant that we observed (overall
median of 3) vs. that of the recent study of Robb et al. [9]
(median¼ 1) may be partially explained by differences in
cohort composition according to subtype [23].Although it is unknown whether subtype-specific viral
properties or immune activation cause AHI symptoms,
observed symptom differences by HIV-1 subtype have
public health significance. Patients with symptomatic
AHI frequently seek healthcare [24–26], presenting
opportunities for diagnosis and immediate treatment.
Unfortunately, guidance is lacking on who should be
evaluated for AHI in sSA [5,27], but we previously
showed that screening at-risk adults for AHI using a
simple algorithm based on seven characteristics would
substantially reduce the number of HIV-1-seronegative
patients requiring testing [27]. The yield of this algorithm
and impact of RNA testing (compared with standard HIV
testing) will be assessed among 2875 adults seeking urgent
care for symptoms in a proof-of-concept trial in Kenya
(R01 AI124968–01A1).
We note that there may have been some subtype
misclassification because of our reliance on the POL
region, and that our insights exclude recombinant
subtypes [28] and subtypes other than A, C, or D.
Additionally, although most infections in discordant
couples were caused by a single strain [29], approximately
a third of MSM in Kenya had multiple strains at infection
[30], some of which may have been obscured in analyses.
Finally, we note that our enrolment viral load was likely a
‘postpeak’ measurement, and the extent to which the
relationship between this measure and peak viral load is
consistent across subtypes will determine the extent to
which our estimated direct effect of subtype reflects the
effect not mediated through peak viral load.
Despite these limitations, the differences that we observed
in ARS symptoms across HIV-1 subtypes suggest that
further investigation of viral characteristics causing
immune activation and control is necessary [23]. As
HIV-1 subtype in a multicentre cohort study Sanders et al. 2545studies in East Africa [9] and South Africa [31]
demonstrate that median peak viral loads are very high,
corresponding with high transmissibility, further research
on the yield of symptom-based AHI screening algorithms
in different regions of sSA is needed.Acknowledgements
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